FOLH1 and prostate carcinoma: Despite challenges in standardization and further research requirements, PET-PSMA imaging represents a significant advancement in prostate cancer management, offering superior diagnostic capabilities and invaluable insights into treatment response dynamics, ultimately leading to improved patient outcomes and quality of life.